Products

What will AGI do for Albendazole oxide?

This classification denotes an antihelminthic agent with the molecular formula C12H15N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J39B52TV34, chemically known as carbamic acid, (5-propylsulfinyl)-1h-benzimidazol-2-yl)-, methyl ester but more generally known as albendazole oxide, which bears US NIH Compound Identifier 83969. European Medicines Agency schedules Albendazole oxide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05296MIG. The term ALBENDAZOLE OXIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). Most nations, for tariff and trade purposes, schedule albendazole oxide under HS 29339990 and SITC 51577. As of Q4 2014, ALBENDAZOLE OXIDE remains US FDA's Preferred Term for this commodity. Albendazole oxide bears US NLM identifiers UMLS ID C2348240 and NCI Concept Code C72157. SMILES: CCC[S+](C1CCC2C(C1)NC([NH]2)NC(=O)OC)[O-].

How AGI delivers it

Four ways AGI delivers for Albendazole oxide

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Albendazole oxide, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Albendazole oxide, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Albendazole oxide connects

measured by

  • Chromatographic Impurity Profilemodel
  • Compound Puritymodel
  • Enantiomeric Ratiomodel
  • Residual Solventmodel